Evaluation of DW Silicone Hydrogel Lens Compared to DW Silicone Hydrogel Lens

This study has been terminated.
(unexpected adverse events)
Sponsor:
Information provided by (Responsible Party):
Coopervision, Inc.
ClinicalTrials.gov Identifier:
NCT01386008
First received: May 22, 2011
Last updated: February 4, 2014
Last verified: February 2014
  Purpose

The purpose of this study is to evaluate the performance of the investigational CooperVision silicone hydrogel lens compared to a currently-marketed silicone hydrogel contact lens up to 30 days of daily lens wear.


Condition Intervention
Myopia
Device: senfilcon A contact lens
Device: investigational enfilcon A

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Coopervision, Inc.:

Primary Outcome Measures:
  • Subjective Comfort Preference - Participants Preference Response [ Time Frame: V1 (Initial), V2 (Day-7), V3 (Day-14), V4 (Day-30) ] [ Designated as safety issue: No ]
    Subjective responses of participants administered by questionnaire and measured on a linear scale (0-100) measured at each visit.

  • Ocular Health [ Time Frame: Change from baseline over 30 days measured at V1 (Initial), V2 (Day-7), V3 (Day-14), V4 (Day-30) ] [ Designated as safety issue: Yes ]
    Ocular health determined by biomicroscopy recorded on a severity scale (0-4) for change from baseline over 30 days.


Secondary Outcome Measures:
  • Investigator Surface Preference [ Time Frame: V1 (Initial), V2 (Day-7), V3 (Day-14), V4 (Day-30) ] [ Designated as safety issue: No ]
    Investigator Surface Preference rated on a linear scale (Lens assessment biomicroscopy: 1=strong R, 2=slight R, 3=No Pref, 4=slight L, 5=strong L)

  • Investigator Fit Preference [ Time Frame: V1 (Initial), V2 (Day-7), V3 (Day-14), V4 (Day-30) ] [ Designated as safety issue: No ]
    Investigator Fit Preference rated on a linear scale (Lens assessment biomicroscopy: 1=strong R, 2=slight R, 3=No Pref, 4=slight L, 5=strong L)


Enrollment: 28
Study Start Date: May 2011
Study Completion Date: June 2011
Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
enfilcon A + senofilcon A
Simultaneous wearing of daily wear contact lenses - investigational enfilcon A contact lenses in one eye and comparator senofilcon A worn in the other
Device: senfilcon A contact lens
senofilcon A spherical contact lens worn in a daily wear modality
Device: investigational enfilcon A
investigational enfilcon A, worn daily wear modality

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Be at least 18 years of age as of the date of evaluation for the study.
  2. Not using any ocular medications
  3. Have a self-reported full eye examination within 2 years.
  4. Have:

    • read the Informed Consent
    • be given an explanation of the Informed Consent
    • indicate understanding of the Informed Consent
    • signed the Informed Consent document.
  5. Be willing and able to adhere to the instructions set forth in this protocol and able to keep all specified appointments.
  6. Be an adapted, current full-time silicone hydrogel or soft contact lens wearer. An adapted full-time wearer is defined as wearing contact lenses on a daily basis for at least 8 hours per day for at least one month prior to participation in the study.
  7. Possess wearable and visually functional eyeglasses.
  8. Be in good general health, based on his/her knowledge.
  9. Require spectacle lens powers between -1.00 and -6.00 diopters sphere with no more than 0.75 diopter of refractive astigmatism in order to have the best spherical equivalent power of -6.50 or less.
  10. Be willing to wear contact lenses in both eyes.
  11. Have manifest refraction Snellen visual acuities (VA) equal to or better than 20/25 (less than or equal to LogMAR 0.10) in each eye.
  12. Upon completing the fitting process with the lenses to be worn in the study, have contact lens Snellen VA equal to or better than 20/30 in each eye.

Exclusion Criteria:

  1. Wearing lenses in a monovision modality and is unwilling to be fit with distance lenses in both eyes. NOTE: Subjects may not wear lenses in a monovision modality at any time during the study as it will interfere with the visual acuity analysis.
  2. Any active participation in another one-day clinical trial within 7 days prior to this study or another dispensing trial within 30 days prior to this study.
  3. Currently pregnant (to the best of the subject's knowledge), is lactating or is planning a pregnancy within the next month.
  4. Has a known sensitivity to ingredients used in the over the counter contact lens care approved for use in the study.
  5. Previous refractive surgery/anterior segment surgery; or current or previous orthokeratology treatment or irregular cornea.
  6. Is aphakic or pseudophakic.
  7. Unable to achieve a satisfactory fit with the lens designs used in the study
  8. Ocular or systemic disease such as, but not limited to: anterior uveitis or iritis (past or present), glaucoma, Sjögren's syndrome, lupus erythematosus, sclerodermia, keratoconus or type II diabetes.
  9. The need for topical ocular medications or any medication which might contradict contact lens wear or which would require the lenses to be removed during the day.
  10. The presence of clinically anterior segment infection, inflammations or abnormalities; such as iritis; or any infection of the eye, lids, or associated structures.
  11. A history of herpetic keratitis.
  12. A known history of corneal hypoesthesia (reduced corneal sensitivity) or active corneal ulcer, corneal infiltrates or fungal infection.
  13. A history of papillary conjunctivitis that has interfered with contact lens wear.
  14. Slit lamp findings that would contraindicate contact lens wear, including but not limited to:

    • Pathological dry eye or associated dry eye symptoms with decreased tear levels and punctuate staining > grade 2
    • Pterygium
    • Corneal scars within the visual axis
    • Corneal edema or corneal staining ≥ grade 2
    • Neovascularization or ghost vessels > 1.0 mm in from the limbus
    • Giant papillary conjunctivitis (GPC) of > grade 2.
    • Seborrheic eczema, seborrheic conjunctivitis or blepharitis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01386008

Locations
United States, California
Clinical Research Center, University of California, Berkeley
Berkeley, California, United States, 94704
United Kingdom
University of Manchester
Manchester, United Kingdom, M13 9PL
Sponsors and Collaborators
Coopervision, Inc.
  More Information

No publications provided

Responsible Party: Coopervision, Inc.
ClinicalTrials.gov Identifier: NCT01386008     History of Changes
Other Study ID Numbers: CV-10-50
Study First Received: May 22, 2011
Results First Received: November 1, 2013
Last Updated: February 4, 2014
Health Authority: United States: Food and Drug Administration
United Kingdom: Medicines and Healthcare Products Regulatory Agency

Additional relevant MeSH terms:
Myopia
Refractive Errors
Eye Diseases

ClinicalTrials.gov processed this record on July 26, 2014